[1] Almdal T P, Sorensen T I. Incidence of parenchymal liver diseases in Denmark, 1981 to 1985: analysis of hospitalization registry data. The Danish Association for the Study of the Liver[J].Hepatology,1991,13:650-655.
[2] gren M, Bergqvist D, Bjrck M, et al. portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23 796 consecutive autopsies[J].World J Gastroenterol,2006,(12): 2115-2119.
[3] Rajani R, Melin T, Bjornsson E, et al. Budd-Chiari syndrome in Sweden: epidemiology, clinical characteristics and survival—an 18-year experience[J].Liver Int, 2009,29:253-259.
[4] Ageno W, Squizzato A, Togna A, et al. Incidental diagnosis of a deep vein thrombosis in consecutive patients undergoing a computed tomography scan of the abdomen: a retrospective cohort study[J].J Thromb Haemost,2012,10(1):158-160.
[5] Thatipelli M R, McBane R D, Hodge D O, et al. Survival and recurrence in patients with splanchnic vein thromboses[J].Clin Gastroenterol Hepatol,2010,8:200-205.
[6] Acosta S, Alhadad A, Svensson P,et al. Epidemiology, risk and prognostic fac-tors in mesenteric venous thrombosis[J].Br J Surg, 2008,95:1245-1251.
[7] Condat B,Valla D.Nonmalignant portal vein thrombosis in adults[J].Nat Clin Pract Gastroenterol Hepatol,2006,3(9):505-515.
[8] De Stefano V, Za T, Ciminello A, et al. Causes of adult splanchnic vein thrombosis in the mediterranean area[J].Mediterr J Hematol Infect Dis, 2011,3(1):e2011.
[9] Dentali F, Galli M, Gianni M, et al. Inherited thrombophilic abnormalities and risk of portal vein thrombosis:a meta-analysis[J].Thromb Haemost,2008,(99):675-682.
[10] De Stefano V, Martinelli I. Splanchnic vein thrombosis: clinical presentation, risk factors and treatment[J].Intern Emerg Med,2010,6:487-494.
[11] Kralovics R, Passamonti F, Buser A S, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders[J].N Engl J Med,2005,352(17):1779-1790.
[12] Colaizzo D, Amitrano L, Tiscia G L, et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenter-ic venous thrombosis[J].J Thromb Haemost,2007,5(1):55-61.
[13] Dentali F, Squizzato A, Brivio L, et al. JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis[J].Blood,2009,113:5617-5623.
[14] Xavier S G, Gadelha T, Rezende S M, et al. JAK2 V617F mutation in patients with thrombosis: to screen or not to screen [J].Int J Lab Hematol,2011,33: 117-124.
[15] Parker C, Omine M, Richards S, et al. Diagnosis and management of paroxysmal nocturnal hemo-globinuria[J].Blood,2005,106(12):3699-3709.
[16] Garcia-Pagán J C, Heydtmann M, Raffa S, et al. TIPS for Budd-Chiari syndrome: long-term results and prognostics factors in 124 patients[J].Gastroenterology,2008,135(3):808-815.
[17] Bijnen S T, Heerde W L, Muus P. Mechanisms and clinical implications of thrombosis in paroxysmal nocturnal hemoglobinuria[J].J Thromb Haemost, 2012,10(1):1-10.
[18] Franchis R. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension[J].J Hepatol,2010,53:762-768.
[19] Kearon C, Akl E A, Comerota A J, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J].Chest, 2012,141(2 Suppl):e419S-494S.
[20] Condat B, Pessione F, Hillaire S, et al. Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant ther-apy[J].Gastroenterology,2001,120:490-497.
[21] Plessier A, Murad S D, Hernandez-Guerra M, et al. Acute por-tal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study[J].Hepatology,2010,51:210-218.
[22] Amitrano L, Guardascione M A, Scaglione M,et al. Prognostic factors in noncirrhotic patients with splanchnic vein throm-boses[J].Am J Gastroenterol, 2007,102(11):2464-2470.
[23] Dentali F, Ageno W, Witt D, et al.Natural history of mesenteric venous thrombosis in patients treated with vitamin K antagonists: a multi-centre, retrospective cohort study[J].Thromb Haemost, 2009,102:501-504.
[24] Senzolo M, Riggio O, Primignani M.Vascular disorders of the liver: recommendations from the Italian Association for the Study of the Liver (AISF) ad hoc committee[J].Dig Liver Dis,2011,43:503-514.
[25] Janssen H L, Garcia-Pagan J C, Elias E, et al.Budd-Chiari syndrome: a review by an expert panel[J]. J Hepatol, 2003,38:364-371.
[26] Darwish-Murad S D, Plessier A, Hernandez-Guerra M, et al.Etiology, management, and outcome of the Budd-Chiari syndrome[J].Ann Intern Med, 2009,151:167-175.